Core Viewpoint - Fengbei Bio (603334.SH) experienced a significant decline in stock price, closing at 57.13 yuan, down 14.42% on November 6, 2023 [1] Group 1: IPO Details - Fengbei Bio was listed on the Shanghai Stock Exchange on November 5, 2025, with an issuance of 35.9 million shares, all new shares, at a price of 24.49 yuan per share [1] - The total funds raised from the issuance amounted to 879.191 million yuan, with a net amount of 794.438 million yuan after deducting issuance costs, exceeding the original plan by 44.438 million yuan [1] Group 2: Fund Utilization - The company disclosed in its prospectus on October 31 that it plans to use the raised funds of 750 million yuan for several projects, including the construction of a 300,000-ton annual production facility for oleic acid methyl ester, a 10,000-ton industrial-grade mixed oil facility, a 50,000-ton agricultural microbial agent facility, a 10,000-ton compound microbial fertilizer facility, and by-products including 50,000 tons of biodiesel and 8,200 tons of glycerin [1] Group 3: Issuance Costs - The total issuance costs for the public offering amounted to 84.7533 million yuan (excluding VAT), with underwriting fees accounting for 58.0598 million yuan [1]

Core Viewpoint - Fengbei Biotechnology Co., Ltd. has successfully listed on the Shanghai Stock Exchange, with a significant opening price increase and high trading volume, indicating strong market interest and investor confidence in the company [1]. Company Overview - Fengbei Biotechnology is a high-tech enterprise focused on the comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [2]. - The controlling shareholder and actual controller of the company is Pingyuan, who directly holds 44.82% of the shares post-IPO and controls a total of 64.03% of the shares through indirect holdings [2]. Financial Performance - The company reported revenues of 170,869.32 million yuan, 172,778.32 million yuan, and 194,801.63 million yuan for the years 2022, 2023, and 2024 respectively, showing a steady growth trend [6]. - Net profits attributable to the parent company were 13,334.79 million yuan, 12,971.18 million yuan, and 12,381.99 million yuan for the same years, indicating a slight decline in profitability [6]. - For the first nine months of 2025, the company achieved revenues of 225,140.52 million yuan, a year-on-year increase of 62.32%, and a net profit of 11,729.88 million yuan, up 35.32% from the previous year [8][9]. IPO Details - The company issued 35.90 million new shares at an issue price of 24.49 yuan per share, raising a total of 879.191 million yuan, with a net amount of 794.438 million yuan after deducting issuance costs [4]. - The funds raised will be used for projects including the construction of production facilities for various bio-based products [4][5]. Future Outlook - The company plans to adjust its customer and product structure in 2024 while maintaining revenue growth, with a focus on managing sales and administrative expenses effectively [3]. - There are inquiries regarding the sustainability of revenue from biofuels and the growth potential of industrial-grade mixed oil sales, indicating a need for careful monitoring of market conditions and operational stability [3].

Core Viewpoint - Company N Fengbei has successfully listed with an opening price of 66.00 yuan, reflecting a significant increase of 169.50% on its first trading day, indicating strong market interest and investor confidence in the company's business model and growth potential [2]. Company Overview - N Fengbei is a high-tech enterprise in the field of comprehensive utilization of waste resources, primarily focusing on the production of resource-based products from waste oils [2]. - The company has developed a production chain that includes waste oils, biodiesel, and bio-based materials, showcasing its commitment to sustainability and innovation in waste resource recycling [2]. Financial Performance - The total number of shares issued by the company is 35.90 million, with an online issuance of 24.21 million shares at a price of 24.49 yuan per share [2]. - The company's issuance price corresponds to a price-to-earnings (P/E) ratio of 30.47, which is significantly lower than the industry average P/E ratio of 64.73 [2]. - The total funds raised from the initial public offering (IPO) amount to 879 million yuan, which will be allocated to projects including the construction of a 300,000-ton annual production facility for methyl oleate, among others [2]. Recent IPO Performance - N Fengbei's first-day performance is part of a broader trend of newly listed stocks, with several companies experiencing substantial increases in their opening prices, indicating a robust market for IPOs in various sectors [3].

Core Viewpoint - Fengbei Bio (603334) has been listed on the Shanghai Stock Exchange, focusing on the comprehensive utilization of waste resources, particularly in producing resource-based products from waste oils [1] Company Overview - Fengbei Bio is a high-tech enterprise in the field of waste resource utilization, primarily engaged in the production of resource-based products from waste oils [1] - The controlling shareholder and actual controller of Fengbei Bio is Pingyuan, who directly held 59.78% of the company's shares before the issuance [1] - After the issuance, Pingyuan directly holds 44.82% of the shares, controlling a total of 64.03% of the company through direct and indirect means [1] Fundraising Details - The total amount raised from the issuance is 879.191 million yuan, with a net amount of 794.437 million yuan after deducting issuance costs [1] - The raised funds will be used for new projects, including the annual production of 300,000 tons of oleic acid methyl ester, 10,000 tons of industrial-grade mixed oil, 50,000 tons of agricultural microbial agents, 10,000 tons of compound microbial fertilizers, and by-products such as 50,000 tons of biodiesel and 8,200 tons of glycerin [1]

Core Points - The company Fengbei Bio is opening its subscription today, with a total issuance of 35.90 million shares, of which 11.48 million shares are for online subscription at a price of 24.49 yuan per share, resulting in a price-to-earnings ratio of 30.47 times [2][3] - The company primarily focuses on the comprehensive utilization of waste oil resources, with a secondary emphasis on oil chemical products [2] Issuance Information - Stock Code: 603334, Stock Abbreviation: Fengbei Bio, Subscription Code: 732334, Issuance Price: 24.49 yuan, Issuance P/E Ratio: 30.47 times, Reference Industry P/E Ratio: 64.73 [3] - Subscription Date: October 27, 2025, Online Issuance Quantity: 11.48 million shares, Total Issuance Quantity: 35.90 million shares, Maximum Subscription Quantity per Account: 11,000 shares, Minimum Subscription Quantity: 500 shares [3] - To participate in the maximum subscription, an investor needs to have a market value of 110,000 yuan [2][3] Fundraising Purpose - The company plans to invest 75 million yuan in new projects, including the annual production of 300,000 tons of oleic acid methyl ester, 10,000 tons of industrial-grade mixed oil, 50,000 tons of agricultural microbial agents, and 10,000 tons of compound microbial fertilizers [3] - An additional 25 million yuan will be allocated to supplement working capital [3] Key Financial Indicators - Total Assets: 12.37 billion yuan in 2024, up from 10.51 billion yuan in 2023 and 9.38 billion yuan in 2022 [3] - Net Assets: 7.56 billion yuan in 2024, compared to 6.30 billion yuan in 2023 and 5.13 billion yuan in 2022 [3] - Operating Revenue: 19.48 billion yuan in 2024, an increase from 17.28 billion yuan in 2023 and 17.09 billion yuan in 2022 [3] - Net Profit: 1.24 billion yuan in 2024, slightly down from 1.30 billion yuan in 2023 and 1.33 billion yuan in 2022 [3] - Basic Earnings per Share: 1.15 yuan in 2024, down from 1.21 yuan in 2023 and 1.26 yuan in 2022 [3] - Weighted Return on Equity: 17.91% in 2024, down from 22.43% in 2023 and 30.57% in 2022 [3]

Group 1 - The company, Suzhou Fengbei Biotechnology Co., Ltd., is a high-tech enterprise in the field of waste resource utilization, primarily producing resource-based products from waste oils [2] - The controlling shareholder and actual controller of the company is Pingyuan, who directly holds 59.78% of the shares and indirectly controls an additional 25.62% through other entities, totaling 85.40% [2] - The company plans to raise 750 million yuan for projects including the production of 300,000 tons of oleic acid methyl ester and 50,000 tons of bio-diesel, among others [2] Group 2 - The company is set to issue shares at a price of 24.49 yuan per share, with an expected total fundraising amount of approximately 879.19 million yuan [2] - After deducting issuance costs of about 84.75 million yuan, the net fundraising amount is projected to be around 794.44 million yuan [2] - The issuance will include 35.9 million shares, with 11.49 million shares available for online subscription and 20.33 million shares for offline allocation [1]

Core Viewpoint - The company, Fengbei Biological Technology Co., Ltd., is set to go public on the Shanghai Stock Exchange, aiming to raise 1 billion yuan for expansion projects in the waste oil resource utilization sector [1][3]. Financial Performance - The company has experienced declining revenue and net profit from 2022 to 2024, with revenues of 1.71 billion yuan, 1.73 billion yuan, and 1.95 billion yuan, and net profits of 135.92 million yuan, 123.04 million yuan, and 115.32 million yuan respectively, indicating a downward trend [3]. - The sales prices of the company's main products have also shown a downward trend during the same period [3][4][5]. Product Pricing - The sales prices for the company's biodiesel formulation products decreased from 0.77 million yuan/ton in 2022 to 0.61 million yuan/ton in 2024, while industrial-grade mixed oil prices fell from 0.91 million yuan/ton to 0.62 million yuan/ton [4]. - The sales prices for biofuels and oil chemical products also declined, with biofuels dropping from 0.98 million yuan/ton to 0.73 million yuan/ton, and oil chemical products from 1.18 million yuan/ton to 0.89 million yuan/ton [5]. Inventory and Liabilities - The company's inventory has been increasing, with values of 104.24 million yuan, 198.38 million yuan, and 242.01 million yuan from 2022 to 2024, indicating a growing stockpile [6]. - The raw materials, primarily waste oil and industrial-grade mixed oil, accounted for a rising proportion of total inventory, increasing from 30.77% in 2022 to 40.71% in 2024 [6]. - The company has a significant amount of current liabilities, with total current liabilities of 373.14 million yuan, 336.64 million yuan, and 358.53 million yuan over the same period, primarily consisting of short-term loans and accounts payable [7][8]. Legal Issues - The company is involved in ongoing litigation related to a fire incident at a leased facility, which resulted in significant inventory losses and subsequent lawsuits from various parties [10][11].

Group 1 - The core viewpoint of the article is that Suzhou Fengbei Biotechnology Co., Ltd. has submitted its IPO registration to the Shanghai Stock Exchange, aiming to raise approximately 750 million yuan for various projects [1] - Fengbei Biotechnology is a high-tech enterprise in the field of comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [1] - The company’s IPO was accepted on June 8, 2023, entered the inquiry stage on July 5, 2023, and was approved on August 7, 2025 [1] Group 2 - The funds raised from the IPO will be invested in projects including the construction of a 300,000-ton annual production facility for methyl oleate, a 10,000-ton industrial-grade mixed oil facility, a 50,000-ton agricultural microbial agent facility, a 10,000-ton compound microbial fertilizer facility, and the production of 50,000 tons of biodiesel and 8,200 tons of glycerin as by-products [1]

Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. has received approval for its initial public offering (IPO) on the Shanghai Stock Exchange, aiming to raise 1 billion yuan for various projects and working capital [1] Financial Performance - The company reported revenues of 1.709 billion yuan in 2022, 1.728 billion yuan in 2023, and projected 1.949 billion yuan in 2024, indicating a growth trend [1] - Net profits for the same years were 133 million yuan in 2022, 130 million yuan in 2023, and a forecast of 124 million yuan in 2024, showing a slight decline [1] - Basic earnings per share were 1.26 yuan in 2022, 1.21 yuan in 2023, and are expected to be 1.15 yuan in 2024, reflecting a downward trend [1] Key Financial Indicators - Revenue for 2024 is projected at 1.948 billion yuan, up from 1.728 billion yuan in 2023 and 1.709 billion yuan in 2022 [1] - The net profit attributable to shareholders is expected to be 123.82 million yuan in 2024, down from 129.71 million yuan in 2023 and 133.35 million yuan in 2022 [1] - The weighted average return on equity is forecasted to be 17.91% in 2024, a decrease from 22.43% in 2023 and 30.57% in 2022 [1]

Group 1 - The core viewpoint of the article is that Suzhou Fengbei Biotechnology Co., Ltd. has successfully passed the IPO review on the Shanghai Stock Exchange, indicating a positive step towards its public listing [1] - Fengbei Biotechnology is a high-tech enterprise in the field of comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [1] - The company aims to raise approximately 750 million yuan through its IPO, which will be invested in various projects including the production of 300,000 tons of oleic acid methyl ester and 10,000 tons of industrial-grade mixed oil [1] Group 2 - The listing committee has requested Fengbei Biotechnology to explain the reasons and rationality behind the expected decrease or stability in sales and management expenses for 2024, despite anticipated adjustments in customer and product structures and continued revenue growth [1] - The committee also requires the company to address the authenticity of sales revenue and expenses related to industrial-grade mixed oil, considering the main operational data and performance changes for 2024 [1] - Additionally, the committee has asked Fengbei Biotechnology to assess the risks of declining biofuel revenue, the sustainability of industrial-grade mixed oil revenue growth, and the stability of the company's operating performance in light of changes in product structure and competitive advantages [2]